Summary Consolidated Statements Of Cash Flows (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Net cash from operating activities:
Net income	$ 5,505	$ 1,829
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	3,557	2,908
Deferred income taxes	41	(801)
Other than temporary investment impairment		3,638
Non-cash compensation	2,140	1,938
Acquired in-process research and development		3,513
Write-down of deferred preservation costs and inventories	270	1,965
Gain on valuation of derivative		(1,345)
Other non-cash adjustments to income	217	170
Changes in operating assets and liabilities:
Receivables	1	(738)
Deferred preservation costs and inventories	2,300	2,495
Prepaid expenses and other assets	(968)	(2,108)
Accounts payable, accrued expenses, and other liabilities	644	358
Net cash flows provided by operating activities	13,707	13,822
Net cash from investing activities:
Acquisition of Cardiogenesis, net of cash acquired	(21,062)
Acquisition of PerClot intangible assets		(5,392)
Capital expenditures	(1,993)	(1,475)
Purchases of restricted securities and investments	(3,569)	(2,705)
Other	(506)	(369)
Net cash flows used in investing activities	(27,130)	(9,941)
Net cash from financing activities:
Principal payments on debt		(315)
Proceeds from financing of insurance policies		1,475
Principal payments on short-term notes payable		(1,086)
Proceeds from exercise of stock options and issuance of common stock	703	236
Repurchase of common stock	(1,607)	(4,295)
Other	(109)	979
Net cash flows used in financing activities	(1,013)	(3,006)
(Decrease) Increase in cash and cash equivalents	(14,436)	875
Effect of exchange rate changes on cash	(11)	6
Cash and cash equivalents, beginning of period	35,497	30,121
Cash and cash equivalents, end of period	21,050	31,002
Supplemental disclosures of cash flow information - non-cash investing activities:
Issuance of common stock for acquisition of PerClot intangible assets		$ 989